Drug company chiefs accept the need for more opennessBMJ 2005; 330 doi: http://dx.doi.org/10.1136/bmj.330.7484.163 (Published 20 January 2005) Cite this as: BMJ 2005;330:163
- Lynn Eaton
Officials from two major pharmaceutical companies—GlaxoSmithKline and AstraZeneca—have accepted that the public needs more openness from the industry.
Dr John Patterson, executive vice president for product strategy, licensing, and business development at AstraZeneca (UK) and Eddie Gray, senior vice president and general manager at GlaxoSmithKline Pharma (UK), were among the witnesses questioned by the House of Commons health select committee last week. They were giving evidence as part of the committee's ongoing inquiry into the influence of the pharmaceutical industry in the United Kingdom.
“There is a feeling that expectations have shifted,” said Mr Gray. “It's like trying to catch a train that is already moving,” he admitted.
Both accepted …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial